ICLR ICON Plc Projected Sales Volume

Graphic logo of ICON Corp (ICLR)

The stable humanitarian status of medicine minimizes external risks for ICON Public (ICLR). The company's future sales figures demonstrate positive dynamics, with the indicator holding at 15.95. Growth is driven by a unique patient base with rare pathologies. Effective integration of acquired assets by management allows the issuer to systematically outperform market revenue forecasts.

ICLR - iconplc.com Company Future Sales Volume over the range 07/04/2022 - 11/14/2026

ICON Public Limited Company (ICLR) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Price Chart ICON|ICLR - Analyst Median Target
- market capitalization data:
Market Capitalization ICON Public Limited Company|ICLR - Company Buyout Price
- book capitalization information:
Book Value per Share ICON|ICLR - Company Net Assets|Market Value to Book Value Ratio iconplc.com|ICLR - Company Assets
- debt and liquidity details:
Debt to Equity ICON Public|ICLR - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio ICON Plc|ICLR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ICON Public Limited Company|ICLR - Long-Term Liabilities|Company Current Liabilities ICON|Quick Ratio iconplc.com
- earnings and market ratios statistics:
ICLR - Company Net Income|Expected Profit ICON Public|ICLR - Price to Earnings Ratio|Forward P/E Multiple iconplc.com|ICLR - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple ICON Public Limited Company|ICLR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) ICON|ICLR - Net earnings per share for the last four quarters|Quarterly EPS earnings growth iconplc.com|ICLR - Net earnings per share growth this year|Net earnings per share growth forecast for next year ICON Public
- total revenue and sales volume data:
ICLR - Company Revenue|Company Projected Revenue ICON Public Limited Company|ICLR - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio ICON Public Limited Company
Fundamental valuation:ICLR ICON Public
Signature product of ICON Corp

ICON Public (ICLR) maintains an impeccable status as a leading CRO in clinical research, which is reflected in the dynamics of the company's projected sales volume—a key indicator of market confidence among pharmaceutical behemoths. This metric transforms static reporting into a continuous data stream, eliminating time lags and allowing investors to assess the asset's fundamental value through the lens of real-time operational activity.

Competitor analysis for ICON Public

Company Projected Revenue IQVIA Holdings Inc. (IQV)|Company Future Sales labcorp.com|Projected Sales Volume MEDP (Medpace)|Company Future Sales Charles River Laboratories International, Inc. (CRL)|Evotec Corp - Projected Sales Volume|Fortrea Clinical (FTRE) - Company Future Sales Volume|lifecore.com (LFCR) - Company Projected Revenue|Company Expected Sales Volume omniab.com (OABI)|Company Projected Revenue Inotiv|Company Revenue Forecast CDMO (Avid Bioservices Inc.)|Company Future Sales Volume CTLT (Catalent Pharma Solutions)|SCPX (Scorpius Holdings, Inc) - Company Future Revenue